What is the recommended valacyclovir dosing regimen for herpes simplex virus infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Valacyclovir Dosing for Herpes

For genital herpes, valacyclovir dosing depends on the clinical scenario: first episode requires 1 gram twice daily for 7-10 days, recurrent episodes need 500 mg twice daily for 3-5 days, and suppressive therapy is 500 mg once daily (or 500 mg twice daily for HIV-infected patients). 1

First Episode Genital Herpes

For initial or first clinical episodes of genital herpes, valacyclovir 1 gram orally twice daily for 7-10 days is the FDA-approved regimen 1. Treatment may be extended beyond 10 days if healing is incomplete 1. This dosing provides comparable efficacy to acyclovir but with improved convenience due to less frequent dosing 2.

Recurrent Episodes

For episodic treatment of recurrent genital herpes, valacyclovir 500 mg twice daily for 3-5 days is effective 1, 3. Studies demonstrate that a 3-day course is equivalent to a 5-day course for key efficacy markers 3. Treatment should be initiated at the first sign of prodrome or within 1 day of lesion onset for maximum benefit 2.

Suppressive Therapy

Immunocompetent Patients

For daily suppression in immunocompetent patients:

  • Standard dosing: 500 mg once daily 1
  • Alternative for ≤9 recurrences/year: 500 mg once daily 1
  • For very frequent recurrences (≥10 episodes/year): 1000 mg once daily is more effective than 500 mg once daily 2

Suppressive therapy reduces recurrence frequency by ≥75% and has been safely used for up to 6 years with acyclovir and 1 year with valacyclovir 2. After 1 year of continuous suppression, reassess the need for ongoing therapy 2.

HIV-Infected Patients

For HIV-infected patients with recurrent genital herpes, valacyclovir 500 mg twice daily is the recommended suppressive dose 1, 4. This higher dose is necessary as once-daily dosing is less effective in this population 4.

Herpes Labialis (Cold Sores)

For cold sores in patients ≥12 years old, valacyclovir 2 grams twice daily for 1 day (two doses 12 hours apart) 1. This single-day regimen should be initiated at the earliest symptom (tingling, itching, or burning) 1.

Special Populations

Renal Impairment

Dose adjustment is mandatory for renal dysfunction 1:

  • CrCl 30-49 mL/min: No reduction for first episode; 500 mg every 24 hours for recurrent episodes
  • CrCl 10-29 mL/min: 500 mg every 24 hours for all indications
  • CrCl <10 mL/min: 500 mg every 24 hours for all indications
  • Hemodialysis: Administer dose after dialysis session 1

Pregnancy

For prophylaxis after 36 weeks gestation in women with history of genital herpes, valacyclovir 500 mg twice daily until delivery to reduce risk of lesions at delivery 5.

Common Pitfalls

  • Do not use valacyclovir 500 mg once daily for patients with ≥10 recurrences/year—this dose is insufficient 2
  • Do not forget renal dose adjustment—elderly patients are particularly at risk for CNS adverse events without dose reduction 1
  • Do not use suppressive therapy to completely prevent transmission—it reduces but does not eliminate asymptomatic viral shedding 2
  • Do not continue suppressive therapy indefinitely without reassessment—recurrence frequency often decreases over time 2

References

Research

Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002

Research

Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004

Related Questions

What is the recommended episodic valacyclovir dosing for an adult with recurrent HSV‑1 or HSV‑2 infection, including adjustments for renal impairment?
What is the recommended valacyclovir (Valtrex) dose for herpes simplex virus prophylaxis in an adult with normal renal function?
Is taking valacyclovir (valacyclovir hydrochloride) 1 g tablets—2 tablets at the first sign of a cold‑sore outbreak and repeating 2 tablets 12 hours later—an appropriate treatment for a herpes simplex virus (HSV‑1) outbreak?
Should a patient with monthly recurrent herpes simplex virus lesions on the nose who uses episodic valacyclovir consider daily suppressive antiviral therapy?
What is the recommended antiviral treatment and dosage for an otherwise healthy adult male with an initial genital herpes simplex infection?
What is the first‑line contraceptive option for a healthy 17‑year‑old female who experiences nausea and abdominal cramping?
What is the differential diagnosis for a cough persisting after an upper respiratory infection?
How do thiazide diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and angiotensin-converting enzyme inhibitors (ACE inhibitors) increase the risk of lithium toxicity?
In a patient with known autoimmune endocrine disease who does not consume alcohol, is new lactose intolerance clinically relevant and should a moderately atrophied pancreas be further evaluated?
Is left-handedness associated with an increased risk of dyslexia?
Is L-lysine recommended for herpes simplex virus type 1 infection, and what dosage should be used?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.